Monaco Asset Management SAM Takes Position in BioNTech SE Sponsored ADR $BNTX

Key Points

• Monaco Asset Management SAM initiated a new position in BioNTech SE Sponsored ADR in the fourth quarter, buying 16,740 shares valued at about $1.59 million.
• BioNTech has seen notable institutional interest, with several large funds increasing their stakes, and 15.52% of the stock is now owned by institutional investors.
• The company also announced a $1 billion share buyback authorized by its board, a move that can signal management believes the stock may be undervalued.

Monaco Asset Management SAM bought a new position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 16,740 shares of the company's stock, valued at approximately $1,594,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. Dodge & Cox lifted its position in BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company's stock worth $359,676,000 after purchasing an additional 2,769,654 shares during the period. BNP Paribas Financial Markets lifted its position in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock worth $150,235,000 after purchasing an additional 474,796 shares during the period. Bank of America Corp DE lifted its position in BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company's stock worth $56,544,000 after purchasing an additional 444,332 shares during the period. SG Americas Securities LLC lifted its position in BioNTech by 1,664.6% in the fourth quarter. SG Americas Securities LLC now owns 365,333 shares of the company's stock worth $34,780,000 after purchasing an additional 344,630 shares during the period. Finally, Millennium Management LLC lifted its position in BioNTech by 910.3% in the third quarter. Millennium Management LLC now owns 246,327 shares of the company's stock worth $24,293,000 after purchasing an additional 276,727 shares during the period. 15.52% of the stock is owned by institutional investors.

Insider Transactions at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the transaction, the chief operating officer directly owned 399,387 shares in the company, valued at $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BNTX has been the subject of several research reports. Bank of America reaffirmed a "buy" rating and issued a $128.00 target price on shares of BioNTech in a research report on Tuesday, March 10th. Jefferies Financial Group reaffirmed a "buy" rating on shares of BioNTech in a research report on Wednesday, March 25th. Morgan Stanley raised their target price on BioNTech from $125.00 to $126.00 and gave the stock an "overweight" rating in a research report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of BioNTech in a research report on Tuesday, March 17th. Finally, Truist Financial upgraded BioNTech to a "strong-buy" rating in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $129.56.

BioNTech Stock Performance

BioNTech stock opened at $95.95 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.80 and a quick ratio of 8.74. The stock has a fifty day moving average price of $94.46 and a two-hundred day moving average price of $99.45. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The firm has a market capitalization of $24.26 billion, a P/E ratio of -16.32 and a beta of 1.33.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The company had revenue of $1.06 billion for the quarter. As a group, analysts anticipate that BioNTech SE Sponsored ADR will post -4.71 EPS for the current fiscal year.

BioNTech announced that its Board of Directors has authorized a share buyback plan on Thursday, May 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to purchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board believes its stock is undervalued.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.